Scarica l'app Stockscreener
6.98
4.18%
0.28
Dopo l'orario di chiusura:
7.12
0.14
+2.01%
Precedente Chiudi:
$6.70
Aprire:
$6.78
Volume 24 ore:
506.25K
Relative Volume:
0.51
Capitalizzazione di mercato:
$464.87M
Reddito:
$80.00M
Utile/perdita netta:
$-74.88M
Rapporto P/E:
-5.9092
EPS:
-1.1812
Flusso di cassa netto:
$-60.38M
1 W Prestazione:
+0.87%
1M Prestazione:
-22.27%
6M Prestazione:
-17.88%
1 anno Prestazione:
+124.44%
Intervallo 1D:
$6.78
$7.16
Intervallo di 1 settimana:
$6.56
$7.16
Portata 52W:
$2.315
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Nome
Fulcrum Therapeutics Inc
Settore
Industria
Telefono
617-651-8851
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
6.98 | 446.22M | 80.00M | -74.88M | -60.38M | -1.1812 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Iniziato | JP Morgan | Overweight |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-07-29 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Downgrade | Stifel | Buy → Hold |
| 2024-09-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-09-25 | Iniziato | Goldman | Neutral |
| 2023-08-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Aggiornamento | Stifel | Hold → Buy |
| 2023-05-04 | Downgrade | Goldman | Buy → Neutral |
| 2023-03-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Downgrade | Stifel | Buy → Hold |
| 2023-02-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Iniziato | Goldman | Buy |
| 2022-03-08 | Iniziato | Oppenheimer | Outperform |
| 2022-03-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2020-10-16 | Iniziato | Piper Sandler | Overweight |
| 2020-08-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-08-12 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
S P Trends: What hedge funds are buying Fulcrum Therapeutics Inc2026 Big Picture & Real-Time Stock Entry Alerts - baoquankhu1.vn
Institution Moves: Is Fulcrum Therapeutics Inc forming higher highs and higher lows2026 Earnings Surprises & Weekly Market Pulse Updates - baoquankhu1.vn
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Growth Value: What hedge funds are buying Fulcrum Therapeutics IncMarket Sentiment Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Profit Recap: Can Fulcrum Therapeutics Inc deliver alpha2026 Retail & Weekly Return Optimization Alerts - baoquankhu1.vn
Fulcrum Extends Pociredir Program With Long-Term Sickle Cell Study - TipRanks
Is Fulcrum Therapeutics Inc benefiting from innovation trends2026 Closing Moves & Stepwise Swing Trade Plans - baoquankhu1.vn
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease - The Manila Times
MedicAlert Foundation, Sickle Cell Disease Association of - GlobeNewswire
Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk - MarketBeat
Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Rises By 19.7% - MarketBeat
Boothbay Fund Management Increases Stake in Fulcrum Therapeutics - National Today
Fulcrum Therapeutics, Inc. $FULC Shares Bought by Boothbay Fund Management LLC - MarketBeat
Wall Street analysts think Fulcrum Therapeutics (FULC) could surge 58.47%: Read this before placing a bet - MSN
219,488 Shares in Fulcrum Therapeutics, Inc. $FULC Bought by Braidwell LP - MarketBeat
Suvretta Capital Management LLC Raises Holdings in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Whats next for Fulcrum Therapeutics Inc stock2026 Winners & Losers & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Aug Macro: What’s next for Fulcrum Therapeutics Inc. stock2026 EndofYear Setup & Free Verified High Yield Trade Plans - baoquankhu1.vn
Fulcrum Therapeutics at Leerink Conference: Strategic Focus on Sickle Cell - Investing.com India
Fulcrum Therapeutics at Leerink Conference: Strategic Focus on Sickle Cell By Investing.com - Investing.com Canada
FULC: Pivotal study planned after robust PIONEER results, with focus on severe sickle cell and U.S. launch - TradingView
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Fulcrum Therapeutics (FULC) Stock Analysis Report | Financials & Insights - Benzinga Japan
Fulcrum Therapeutics stock may face pressure on Ipsen withdrawal, Stifel says - Investing.com Canada
Why Fulcrum Therapeutics Inc. stock appeals to dividend seekersJuly 2025 Highlights & Daily Price Action Insights - Naître et grandir
Bullish analyst sentiment on Fulcrum Therapeutics (FULC) following positive updates from Phase 1b PIONEER study - MSN
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bull Run: Can Fulcrum Therapeutics Inc disrupt its industryJuly 2025 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
New Fulcrum hire gets 34,000 stock options with 4-year vesting - Stock Titan
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - 富途牛牛
Hedge Fund Moves: Is Fulcrum Therapeutics Inc part of any ETFJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
FULC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 7.5%Here's Why - MarketBeat
FULC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Winners Losers: Can Fulcrum Therapeutics Inc keep up with sector leadersBond Market & Stepwise Swing Trade Plans - baoquankhu1.vn
What is HC Wainwright’s Forecast for FULC Q1 Earnings? - Defense World
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion (NASDAQ:FULC) - Seeking Alpha
Fulcrum Therapeutics, Inc. (FULC): Analyst Ratings Suggest 111% Upside Potential – Is It Time to Buy? - DirectorsTalk Interviews
HC Wainwright Has Optimistic Outlook of FULC Q1 Earnings - MarketBeat
RBC Capital Remains a Hold on Fulcrum Therapeutics (FULC) - The Globe and Mail
FY2030 Earnings Forecast for FULC Issued By HC Wainwright - Defense World
Fulcrum Therapeutics move lower ‘overdone,’ says Stifel - Yahoo Finance
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Fulcrum Therapeutics stock falls as sickle cell trial misses target - Investing.com Australia
Fulcrum Therapeutics stock falls as sickle cell trial misses target By Investing.com - Investing.com Canada
Leerink reiterates Fulcrum Therapeutics stock rating on SCD data By Investing.com - Investing.com Canada
Fulcrum Therapeutics shares fall on profit-taking, Oppenheimer says By Investing.com - Investing.com Canada
Fulcrum Therapeutics Inc Azioni (FULC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):